Product image of Meliglix (Sitagliptin) supplied by GNH India

Meliglix

Active Ingredient:
Sitagliptin
Origin:
EU

Meliglix (Sitagliptin)

Sitagliptin, the active ingredient in Meliglix, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is prescribed to improve glycaemic control in adults with type 2 diabetes mellitus, typically as part of a regimen that includes diet and exercise.

GNH India supplies Meliglix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions, including the European Union and Asia‑Pacific markets.

Manufacturer / TM Owner

Pharmazac Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Sitagliptin is used to manage hyperglycaemia in the type 2 diabetes therapeutic pathway.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels when used alone with diet and exercise.
  • Type 2 diabetes mellitus (combination with metformin): provides additional glycaemic reduction in patients inadequately controlled on metformin.
  • Type 2 diabetes mellitus (combination with insulin): enhances insulin efficacy and may reduce required insulin dose.

How It Works

  • Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which degrades the incretin hormones glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). By blocking DPP‑4, sitagliptin increases endogenous GLP‑1 and GIP levels, leading to glucose‑dependent stimulation of insulin secretion, suppression of glucagon release, and delayed gastric emptying, thereby improving post‑prandial and overall glycaemic control without causing hypoglycaemia when used alone in most patients.

Side Effects

Sitagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nasopharyngitis: mild inflammation of the nose and throat.
  • Headache: transient head pain of varying intensity.
  • Upper respiratory tract infection: symptoms such as cough and sore throat.
  • Gastrointestinal discomfort: includes nausea, abdominal pain or dyspepsia.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe allergic reactions: including angioedema, rash or anaphylaxis.
  • Bullous pemphigoid: autoimmune blistering skin disorder.

Precautions & Warnings

When prescribing sitagliptin, clinicians should consider several safety considerations.

  • Renal function: assess creatinine clearance and adjust dose in moderate to severe impairment.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Hypoglycaemia risk: monitor closely when combined with insulin or sulfonylureas.
  • Cardiovascular disease: evaluate benefits in patients with established heart disease.
  • Elderly patients: start at lower dose and monitor for adverse effects.
  • Store at ambient temperature: keep tablets in original container, protect from moisture and excessive heat.

Avoid Interactions

Sitagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Concomitant use with other DPP‑4 inhibitors (e.g., saxagliptin, alogliptin): may increase risk of adverse effects.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce sitagliptin plasma concentrations.
  • Combination with high‑dose insulin or sulfonylureas: can cause severe hypoglycaemia.

Moderate Interactions (Monitor Closely)

  • Diuretics: may alter glucose homeostasis.
  • ACE inhibitors or ARBs: monitor blood pressure and renal function.
  • Beta‑blockers: may mask hypoglycaemia symptoms.
  • NSAIDs: watch for renal function changes.
  • Anticoagulants (e.g., warfarin): periodic INR monitoring recommended.

Frequently Asked Questions

Meliglix contains sitagliptin, which is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus. It is used as part of a comprehensive treatment plan that includes diet, exercise, and, when needed, other antidiabetic agents.

Sitagliptin blocks the DPP‑4 enzyme, preventing the breakdown of the incretin hormones GLP‑1 and GIP. Higher levels of these hormones stimulate insulin release and suppress glucagon when blood glucose is elevated, helping to lower overall blood sugar without causing hypoglycaemia when used alone.

The appropriate dose of Meliglix is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for sitagliptin during pregnancy and lactation are limited. It is generally recommended to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Meliglix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Sitagliptin belongs to the DPP‑4 inhibitor class, which offers glucose‑dependent insulin secretion and a low risk of hypoglycaemia compared with sulfonylureas. Unlike metformin, it does not affect gastrointestinal absorption, and unlike insulin, it is not injectable. It is often combined with other agents to achieve target glycaemic control.

Meliglix tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and excessive heat. Keep the product out of reach of children and avoid exposure to direct sunlight.

Meliglix is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious adverse events associated with sitagliptin include pancreatitis, severe allergic reactions such as angioedema or anaphylaxis, and rare skin conditions like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, swelling of the face or throat, or unexplained skin blisters.

Meliglix should be avoided in patients with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is advised in individuals with severe renal impairment, a history of pancreatitis, or those taking other DPP‑4 inhibitors. The prescriber will assess suitability on a case‑by‑case basis.

Medically reviewed by

Dr. Shweta Ashok More

M.Pharm (Quality Assurance), Ph.D. (Medicinal Chemistry), GNH India Pharmaceuticals Limited · Reviewed 9 Sep 2026

Published by GNH India Pharmaceuticals Limited · Last updated

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT